Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
42.63
+0.68 (+1.62%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
November 16, 2023
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...
Via
Benzinga
Current Analysis: GSK Plc
November 16, 2023
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales.
Via
Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
November 15, 2023
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
November 13, 2023
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi
Via
Benzinga
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
November 13, 2023
From
GSK plc
Via
Business Wire
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Peering Into GSK's Recent Short Interest
October 26, 2023
Via
Benzinga
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
November 08, 2023
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth
Via
InvestorPlace
GSK is a remedy for the winter investment blahs
November 07, 2023
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
3 Healthcare Stocks Getting Help From the Aging Population
November 06, 2023
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions.
Via
InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
November 02, 2023
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns.
Via
InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
November 02, 2023
The company issued below-consensus sales views for 2023 and 2024.
Via
Investor's Business Daily
Price Over Earnings Overview: GSK
October 24, 2023
Via
Benzinga
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
November 01, 2023
The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine.
Via
Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
November 01, 2023
GSK plc (NYSE: GSK) reported Q3 FY23 s
Via
Benzinga
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
November 01, 2023
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
October 31, 2023
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have
Via
Benzinga
Earnings Scheduled For November 1, 2023
November 01, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Via
Benzinga
Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates
October 30, 2023
GSK plc (NYSE: GSK)
Via
Benzinga
GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales
October 30, 2023
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19...
Via
Benzinga
Exposures
COVID-19
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
From
23andMe, Inc.
Via
GlobeNewswire
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
October 28, 2023
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its...
Via
Talk Markets
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
October 27, 2023
Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less.
Via
InvestorPlace
3 Deeply Undervalued Growth Stocks
October 27, 2023
As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks.
Via
InvestorPlace
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 27, 2023
From
Alector, Inc.
Via
GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
October 25, 2023
From
GSK plc
Via
Business Wire
Bank Of America, Mastercard, NRA And Others Are Lobbying For Cannabis Banking Reform — Who Knew?
October 22, 2023
Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third quarter of 2023.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
October 14, 2023
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...
Via
Talk Markets
GSK: Pharma Giant Prioritizing Shareholder Dividends
October 13, 2023
A good hunting ground for dividend stocks is often companies from which Wall Street wants to see strong performance in the short-term, while its long-term prospects are actually what are most bright.
Via
Talk Markets
Google AI-Powered Chatbot's Ethical Concerns, MGM Hackers Waited For Days Before Issuing Financial Demands, Costco Accused Of Sharing Confidential Health Data With Facebook: Today's Top Stories
October 11, 2023
Bloomberg Google's AI Dilemma - Bard's Promise Versus Ethical Concerns
Via
Benzinga
Topics
Artificial Intelligence
Hacking
Exposures
Artificial Intelligence
Information Security
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.